Antigen Background The CD4 molecule (T4) is a single chain transmembrane glycoprotein with a molecular weight of 59 kD. The CD4 antigen is expressed on a T cell subset (helper/inducer) representing 45% of peripheral blood lymphocytes and at a lower level on monocytes and germinal center macrophages. Most cases of cutaneous T cell lymphoma, including mycosis fungoides, express the CD4 antigen and HTLV-1 associated adult T cell leukemia/lymphoma is...

Antigen Background The CD45RO molecule, a 180 kD isoform of CD45, is reported to be expressed on 48% of peripheral blood T lymphocytes, 37% of CD4 positive lymphocytes, 80% of thymocytes and on the majority of T cell malignancies. Monocytes and granulocytes show surface expression of the antigen whereas tissue macrophages exhibit cytoplasmic expression. Disclaimer CD45RO is recommended for the detection of specific antigens of interest in normal ...

Antigen Background The CD43 antigen is expressed on the membrane and in the cytoplasm of T cells and cells of myeloid lineage. The molecule itself exhibits molecular weight heterogeneity with bands of 90 to 140 kD observed on SDS-PAGE between different cell lines. Cells expressing the CD43 antigen are reported to include normal and neoplastic T cells. A small proportion of B cell chronic leukemias and diffuse large B cell lymphomas are also repor...

Antigen Background The CD45 antigen (leukocyte common antigen) is a family of five or more high molecular weight glycoproteins present on the surface of the majority of the human leukocytes (including lymphocytes, monocytes and eosinophils) but absent from erythrocytes and platelets. Various isoforms of CD45 are generated by alternative splicing of three exons. Expression of CD45 is necessary for signaling through the T cell receptor. Disclaimer ...

It’s Time for TIME Alexander “Sandy” Borowsky Professor of Pathology and Laboratory Medicine Center for Immunology and Infectious Diseases Disclosures Bristol-Meyers Squibb/Celgene: Funded through Investigator Sponsored Research (ISR) program. Discovery proposal. Leica/Aperio: Funded to run the “Genesis” study for primary diagnosis from whole slide images. Honorarium for this presentation. Histolix: Slide-free histology (Levenson and Fereidouni). Pfizer: Pfizer Protocol A9001502, Treatment Resistance Following Therapies (TRANSLATE) site PI. Agenda: In contracting to join the “FLEX” registry. None of these has actually paid me, only funding for the research projects. Objectives • Introduction into the complexity of the TIME and the development of new cancer treatments though di...

Introduction to immuno oncology 1. Introduction to Immuno-Oncology Michael Bates, MD Oncology Strategy, Medical and Scientific Affairs Cepheid Sunnyvale, CA Cepheid and Leica Biosystems are Danaher Companies 2. Overview • History of Immuno-Oncology • Types of Immunotherapy • Immunomodulatory agents • Personalized Cancer Vaccines • CAR-T cell therapy • Immune Checkpoint Inhibitors • Focus: Immune Checkpoint Biomarkers 3. Evolution of Cancer Immunotherapy • William Coley – 1890s surgeon • Coley’s toxin… • BCG, IFN-alpha, IL-2 • IL-2 applications in melanoma and RCC proved that advanced metastatic cancers can be controlled in some patients by stimulating T cells with cytokines • Critical development • CTLA-4 shown to be inhibitory for T cell responses by James Allison and Jeff Blu...

The potential for non-invasive tests that provide equivalent research and diagnostic value as can be obtained from tissue biopsies is real, but not yet realized. Tissue biopsies allow for identification, phenotyping and molecular analysis of cancer and...

Phenotyping Tumor Microenvironment Using DNA Barcoded Multiplex Technology Chifei Sun GSK IVIVTBIBCellular Biomarkers Collegeville, PA I have no conflict of interests with Leica Biosystems, Ultivue and Indica Labs. – All the materials used in this presentation are for educational purpose only. – The human biological samples were sourced ethically, and their research use was in accord with the terms of the informed consents under an IRB/EC approved protocol. Statement 9/25/2020 2 Understand the complexity of tumor microenvironment and its importance in drug development – Introduce the Ultivue DNA barcoding and exchange technology for multiplex immunofluorescence – Highlight the processes of image fusion, spatial analysis and colocalization of markers on individual cells Learning...

Biomarkers AE1/AE3 (1) AMACR (2) BCL6 (1) CD163 (2) CD20 (2) CD3 (9) CD4 (5) CD68 (5) CD8 (10) CDX2 (2) CK20 (5) Ck5 (4) ...